Context Therapeutics Inc. (NASDAQ:CNTX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.17.

CNTX has been the topic of several recent analyst reports. Zacks Research downgraded shares of Context Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 12th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Lifesci Capital cut shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.24 on Wednesday. The business’s 50 day moving average price is $0.37 and its 200-day moving average price is $1.13. Context Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). On average, equities research analysts expect that Context Therapeutics will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently modified their holdings of CNTX. BlackRock Inc. purchased a new stake in shares of Context Therapeutics in the 2nd quarter worth $3,417,000. Octagon Capital Advisors LP bought a new position in shares of Context Therapeutics during the 1st quarter worth $13,755,000. Blue Owl Capital Holdings LP purchased a new position in shares of Context Therapeutics during the second quarter valued at $1,625,000. ADAR1 Capital Management LLC purchased a new position in shares of Context Therapeutics during the second quarter valued at $416,000. Finally, Timothy G. Youngquist 2020 Irrevocable Trust purchased a new position in shares of Context Therapeutics during the second quarter valued at $110,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.